- Home
- SERV vs RCUS Comparison
SERV vs RCUS Comparison
Compare SERV & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERV
- RCUS
- Stock Information
- Founded
- SERV 2017
- RCUS 2015
- Country
- SERV United States
- RCUS United States
- Employees
- SERV N/A
- RCUS N/A
- Industry
- SERV Industrial Specialties
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- SERV Consumer Discretionary
- RCUS Health Care
- Exchange
- SERV Nasdaq
- RCUS Nasdaq
- Market Cap
- SERV 351.2M
- RCUS 727.1M
- IPO Year
- SERV N/A
- RCUS 2018
- Fundamental
- Price
- SERV $6.56
- RCUS $8.53
- Analyst Decision
- SERV Strong Buy
- RCUS Buy
- Analyst Count
- SERV 3
- RCUS 11
- Target Price
- SERV $17.00
- RCUS $25.67
- AVG Volume (30 Days)
- SERV 3.7M
- RCUS 1.2M
- Earning Date
- SERV 05-08-2025
- RCUS 05-06-2025
- Dividend Yield
- SERV N/A
- RCUS N/A
- EPS Growth
- SERV N/A
- RCUS N/A
- EPS
- SERV N/A
- RCUS N/A
- Revenue
- SERV $1,812,483.00
- RCUS $141,000,000.00
- Revenue This Year
- SERV $497.96
- RCUS N/A
- Revenue Next Year
- SERV $425.24
- RCUS $25.77
- P/E Ratio
- SERV N/A
- RCUS N/A
- Revenue Growth
- SERV 773.30
- RCUS N/A
- 52 Week Low
- SERV $1.77
- RCUS $6.50
- 52 Week High
- SERV $24.35
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- SERV N/A
- RCUS 51.50
- Support Level
- SERV N/A
- RCUS $7.06
- Resistance Level
- SERV N/A
- RCUS $9.35
- Average True Range (ATR)
- SERV 0.00
- RCUS 0.53
- MACD
- SERV 0.00
- RCUS 0.08
- Stochastic Oscillator
- SERV 0.00
- RCUS 64.19
About SERV Serve Robotics Inc. Common Stock
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.